{
    "clinical_study": {
        "@rank": "97331", 
        "acronym": "BBI", 
        "arm_group": {
            "arm_group_label": "Biochemo + Bevacizumab then Ipilimumab", 
            "arm_group_type": "Experimental", 
            "description": "Single arm:  Biochemotherapy with 4 cycles at 3 week intervals of Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days each cycle; then ipilimumab 3mg/kg q 21 days x 4, then q 3 months x 8 for total 3 years."
        }, 
        "brief_summary": {
            "textblock": "A phase I-II study of treatment of metastatic melanoma using induction therapy with\n      Biochemotherapy plus Bevacizumab followed by consolidation therapy with Ipilimumab (BBI)."
        }, 
        "brief_title": "Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Metastatic Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "A phase I-II study of treatment of metastatic melanoma using induction therapy with\n      Biochemotherapy (Temodar,Cisplatin, Velban,IL2 and IFN)plus Bevacizumab followed by\n      consolidation therapy with Ipilimumab (BBI)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Stage 4 or unresectable stage 3 metastatic melanoma with or without measurable\n             disease\n\n          2. Age 18-70 years old\n\n          3. Adequate pulmonary and cardiac function for high-dose IL-2\n\n          4. PS 0-2\n\n          5. Previous ipilimumab therapy will not exclude patients, but patients with previous\n             ipilimumab will have separate efficacy analysis\n\n        Exclusion Criteria:\n\n          1. Brain metastases\n\n          2. Creatinine > 2x ULN; bilirubin > 3, WBC < 3500, Platelets < 100,000, Hgb < 9\n\n          3. Another active malignancy\n\n          4. Gastrointestinal tract metastases except rectal metastases or primary are allowable\n\n          5. Previous therapy for metastatic disease with chemotherapy of duration over 3  months\n             or with high-dose interleukin-2\n\n          6. History of colitis or autoimmune disease such as lupus or rheumatoid arthritis\n\n          7. Bevacizumab-related contraindications: Hemoptysis or history of severe bleeding,\n             uncontrolled hypertension, proteinuria with protein/creatinine ratio > 1, acute\n             myocardial infarction within 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 4, 2011", 
        "has_expanded_access": "Yes", 
        "id_info": {
            "nct_id": "NCT01743157", 
            "org_study_id": "BBI Total Therapy"
        }, 
        "intervention": {
            "arm_group_label": "Biochemo + Bevacizumab then Ipilimumab", 
            "description": "Bevacizumab 7.5mg/kg week 1,repeat weeks 4,7,10 (cycles 2, 3, & 4)", 
            "intervention_name": "Biochemo + bevacizumab then ipilimumab", 
            "intervention_type": "Drug", 
            "other_name": [
                "Avastin,", 
                "Temodar,", 
                "Platinol,", 
                "Velban,", 
                "interleukin-2,", 
                "Intron-A,", 
                "Yervoy"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Bevacizumab", 
                "Interleukin-2"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94115"
                }, 
                "name": "San Francisco Oncology Associates"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I-II Study of Treatment of Metastatic Melanoma Using Induction Therapy With Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab (BBI)", 
        "overall_official": {
            "affiliation": "California Pacific Medical Center", 
            "last_name": "David R Minor, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Determine the incidence of grade 4 bevacizumab-related toxicities and grade 3 proteinuria when bevacizumab is given with biochemotherapy to patients with metastatic melanoma for up to 3 years.", 
            "measure": "A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy and Bevacizumab followed by consolidation therapy with Ipilimumab (BBI)", 
            "safety_issue": "Yes", 
            "time_frame": "Primary Objective"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01743157"
        }, 
        "responsible_party": {
            "investigator_affiliation": "California Pacific Medical Center Research Institute", 
            "investigator_full_name": "David Minor, MD", 
            "investigator_title": "Medical Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Compare median and overall progression-free survival to previously published historical control group of 135 patients receiving biochemotherapy followed by pulse IL-2, and also patients in the study of Weber et al (Reference 9) of ipilimumab in previously untreated patients for up to 4 years.", 
            "measure": "A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy and Bevacizumab followed by consolidation therapy with Ipilimumab (BBI)", 
            "safety_issue": "No", 
            "time_frame": "Secondary Objective"
        }, 
        "source": "California Pacific Medical Center Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "California Pacific Medical Center Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}